Security record · archived quarter
CRVS
Corvus Pharmaceuticals, Inc. · Healthcare · Biotechnology
7Tracked holders
0Δ holders
7.32MShares held
$38.63MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.7% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 34.72M | $518.70M | +11 | −5 |
| Q1 2026 | 64 | +8 | 30.80M | $450.00M | +15 | −7 |
| Q4 2025 | 56 | +2 | 25.04M | $192.77M | +2 | n/a |
| Q3 2025 | 14 | 0 | 18.71M | $137.91M | +2 | −2 |
| Q2 2025 | 11 | -1 | 17.31M | $69.23M | +1 | −2 |
| Q1 2025 | 9 | +2 | 6.14M | $19.53M | +2 | n/a |
| Q4 2024 | 7 | -1 | 4.46M | $23.85M | n/a | −1 |
| Q3 2024 | 7 | 0 | 7.32M | $38.63M | n/a | n/a |
| Q2 2024 | 7 | n/a | 7.37M | $13.41M | n/a | n/a |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 5.56M | -6.7% | $29.37M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 563.01K | +22.4% | $2.97M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 386.59K | -31.4% | $2.04M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 323.21K | +333.5% | $1.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 311.29K | +52.1% | $1.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 97.07K | +83.1% | $512,545 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 71.55K | +49.7% | $377,795 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 163 holders, 69.83M shares, $976.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API